Comments Group: Patented cell line. Part of: LL-100 blood cancer cell line panel. Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6670. Population: Caucasian. Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections. Characteristics: IL2 dependent. Characteristics: Does not express FCGR3A/CD16. Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ=ACC-488). Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV). Omics: Deep exome analysis. Omics: Transcriptome analysis by microarray. Omics: Transcriptome analysis by RNAseq. Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing. Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178. Cell type: Natural killer cell; CL=CL_0000623.